SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to its FDA-approved drug for a specific type of leukemia, though the drug carries warnings about potentially fatal side effects, leading to concerns about its safety profile.  Despite these concerns, some community members believe the drug's approval doubles its addressable market and view this as a long-term play, while others suggest a potential acquisition. Discussions also include potential market manipulation and the possibility of a short squeeze.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending due to retail investors targeting a potential short squeeze, evidenced by high borrowing costs and significant social media discussion around depleting float. The community is actively discussing strategies to pressure short sellers, with some users calling for a coordinated effort to recall lent shares. Bullish sentiment seems tied to expectations around insiders increasing their positions.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk ($TTD) is experiencing volatility, with community members noting a lack of clear news catalysts for recent price swings. Despite broader market rallies, $TTD struggles to hold gains, leading to frustration among investors and speculation about market manipulation. Some investors point to a potential inverse head and shoulders pattern and analyst price target reiterations as positives, while others highlight the company's upcoming earnings release and potential benefits from shifts in the ad tech landscape.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc ($UUUU) is experiencing significant price volatility, driven by unusual options activity and discussions around its strategic positioning in the uranium and rare earth elements sectors. Community members are actively debating whether recent price movements are due to manipulation, insider trading, or broader market corrections, with some highlighting the company's potential to benefit from government contracts and the shift towards domestic resource independence. The stock's price action is also being influenced by news of a joint venture in Australia and increased investment in the company.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as analysts are raising price targets, citing increasing DRAM prices and AI demand, with UBS setting a target of $245 and Citi at $240. The community is closely watching for a breakout above $200 and speculating about potential partnerships, particularly with OpenAI, while also weighing its removal from the Chinese server market. Bullish sentiment revolves around Micron's undervalued status compared to its peers and the expectation of strong earnings reports driving further gains.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford's stock is trending downwards as a fire at a key aluminum supplier is expected to disrupt production, particularly for the profitable F-150 trucks. The community is debating whether this dip is an overreaction, a buying opportunity, or a sign of deeper issues with Ford's supply chain management and future guidance. Discussions also involve potential tariff relief and its impact on Ford's financials amid the aluminum shortage.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a significant surge potentially fueled by news of insider buying and a milestone payment from Merck related to their Alzheimer's program. The community is actively discussing the low float and potential for a short squeeze, with some speculating about a potential run to double digits. However, some traders caution about potential dilution.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining Corp is trending amid discussions of a potential Newmont takeover of Barrick's Nevada gold assets and Scotiabank upgrading its rating to Sector Outperform. Community members are also discussing the company's solid liquidity and potential merger opportunities. Some are also pointing out recent job cuts with others expecting gold to soar further.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

DECK is trending as the stock experiences high volatility following earnings and revised guidance, sparking debate about its valuation and future growth prospects. Community discussion revolves around whether the dip presents a buying opportunity or if deeper issues with consumer demand and tariffs will continue to pressure the stock. Analysts are weighing in with mixed opinions, contributing to the uncertainty surrounding DECK.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVDA is trending as the community discusses its continued strength in the semiconductor market, fueled by AI prospects and key partnerships, even amidst concerns of bubble territory. Recent advancements in graphics technologies and speculation around upcoming announcements at the GTC conference are adding to the bullish sentiment. Traders are closely watching for a potential breakout towards the $200 level, while also weighing the impact of broader market factors and potential government actions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline

Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS

Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised 

Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.

Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?

Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.

Shares of Revolution Medicines, Disc Medicine, and Regeneron Pharmaceuticals rose in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) announced the first group of drugs selected for expedited review under its new National Priority Voucher pilot program.In after-hours trading on Thursday,&nbsp;<a href="https://stocktwits.com/symbol/RVMD">Revolution Medicines</a> jumped 9%,&nbsp;<a href="https://stocktwits.com/symbol/IRON">Disc Medicine</a> surged 17%, and&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals</a> edged up 0.1%.FDA Names 9 Drugs For Accelerated ReviewThe FDA said nine products have been chosen for the fast-track review process, which shortens decision timelines from the usual 10–12 months to just one or two months once a complete application is filed.The selected drugs include Merck KGaA’s fertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and ketamine for domestic manufacturing of a general anesthetic.&nbsp;Also on the list are Revolution Medicines’ RMC-6236 for pancreatic cancer, Disc Medicine’s bitopertin for porphyria, Achieve Life Sciences’ cytisinicline for nicotine vaping addiction, Dompe’s cenegermin-bkbj for blindness, and Augmentin XR for domestic manufacturing of a common antibiotic.FDA Commissioner Highlights Expedited Review EffortFDA Commissioner Marty Makary said the initiative could shorten FDA decision times from a year to "a matter of weeks” by moving promising or high-impact therapies to the front of the review line.Makary said some of the drugs selected for vouchers, including one that uses ketamine as a general anesthetic, will be manufactured in the United States. He described Regeneron’s DB-OTO, a gene therapy for congenital deafness, as “an exciting treatment,” noting that “some of these kids got normal hearing from this amazing treatment.”He added that this is just the first round of vouchers, with additional selections expected in the coming weeks.How Stocktwits Traders Reacted To FDA’s Fast-Track ListOn Stocktwits, retail sentiment toward Revolution Medicines was ‘extremely bullish’ with ‘extremely high’ message volume, while Disc Medicine saw ‘neutral’ sentiment amid similarly ‘extremely high’ activity, and Regeneron registered ‘neutral’ sentiment with ‘normal’ engagement levels.One&nbsp; user said they expect Regeneron shares to climb steadily, projecting the stock could reach the $800-$900 range within two years.&nbsp;<stembedurl>https://stocktwits.com/Iwannagofast1/message/632653980</stembedurl>Another bullish trader suggested Revolution Medicines could be an attractive takeover candidate, potentially fetching twice its current value.<stembedurl>https://stocktwits.com/ChessGM/message/632555600</stembedurl>So far this year, Revolution Medicines shares have gained 14%, Disc Medicine is up 17%, while Regeneron has declined 20%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Equity

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)

Regeneron's DB-OTO gene therapy shows hearing gains in nearly all CHORD study participants, with durable and meaningful improvements.

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape Next-Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire VANCOUVER, BC, Oct. 15, 2025 USA News Group...

A Canaccord analyst on Monday highlighted the risks associated with the U.S. Food and Drug Administration’s ‘Official Action Indicated’ designation on Catalent Indiana LLC, a third-party fill-finish facility.Novo Nordisk's (NVO) update that the FDA has classified Catalent Indiana LLC as "Official Action Indicated" raises the risk of further delay for Regeneron’s (REGN) Eylea HD prefilled syringes, as they are produced at the same site, the analyst noted. Catalent Indiana was acquired by Novo Nordisk (NVO) in December.Notably, Regeneron had <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">said</a> in August that the FDA extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions until the fourth quarter, owing to issues identified at the fill-finish facility.Regeneron is not the only company whose submissions have been delayed or denied following the FDA’s site inspection at Catalent's Indiana facility. Last month, the FDA <a href="https://stocktwits.com/news-articles/markets/equity/scholar-rock-in-spotlight-after-fda-refuses-to-approve-muscular-atrophy-treatment/chDhUSIR35Z">refused</a> to approve Scholar Rock’s (SRRK) Apitegromab drug for the treatment of patients with spinal muscular atrophy over concerns identified during the inspection of Catalent Indiana's facility.Breaches at Catalent Indiana’s facility have been classified as "Official Action Indicated," Scholar Rock said in a statement. The serious designation means regulatory and/or administrative actions are recommended to resolve the concerns identified.Scholar Rock said that it continues to work closely with Novo and has requested a meeting with the FDA to discuss the next steps for resubmitting its Apitegromab drug application.While REGN shares traded 2% lower at the time of writing, <a href="https://stocktwits.com/symbol/SRRK">SRRK stock</a> fell 12%. While retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, sentiment around SRRK rose from ‘neutral’ to ‘bullish’ territory.<figure class="image"><img style="aspect-ratio:620/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_1_20_48_PM_png_df71d2ade1.webp" alt="REGN's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="620" height="61"><figcaption>REGN's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:623/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_13_at_1_21_27_PM_png_5e9ad0811c.webp" alt="SRRK's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits" width="623" height="63"><figcaption>SRRK's Sentiment Meter and Message Volume as of 1:21 p.m. ET on Oct. 13, 2025 | Source: Stocktwits</figcaption></figure>SRRK stock has dropped about 20% this year, while REGN lost 22%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-approves-changed-recommendations-for-use-of-abbvie-rinvoq/ch6SFlFR3lG">AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Are Regeneron And Scholar Rock Shares Falling On Monday?

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$578.60
Prev Close	$575.69
Open	$578.50
Dividend Yield	0.00%
50-Day Moving Average	$576.07
Beta	0.60
Avg. Volume	1.08M
PE Ratio	14.51

52-Week High	$943.83
52-Week Low	$476.49
Market Capitalization	$61.02B
EPS (Annual)	$38.34
Price to Book	2.05
Revenue Per Employee	$940,156.23
Enterprise Value/EBITDA	N/A

REGN
Regeneron Pharmaceuticals, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest REGN News

REGNRegeneron Pharmaceuticals, Inc.